Prevalence of cardiovascular risk factors, target organ damage, and subclinical and symptomatic cardiovascular disease in a national population of patients with chronic myeloid leukemia

Introduction: Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has improved the life expectancy of these patients.However, TKIs have been related to an increase in cardiovascular events.These occur especially in patients who already had cardiovascular risk factors (CVRF).Material and methods: An observational cross-sectional study of patients with CML under treatment with TKI was conduced.The prevalence of CVRF, target organ damage and subclinical and symptomatic atherosclerotic cardiovascular disease (ASCVD) was studied.Results: 73 patients were included.63.01% were male.The median age was 56 years (IQR 45 -67,50).47.95% had high blood pressure, 17.33% diabetes mellitus, 40.79% dyslipidemia, 50.68% overweight, 26.03 obesity and 21.92% were smokers.19.20% presented microalbuminuria, 8.20% left ventricular hypertrophy and 19.18% chronic kidney disease.32.90% had high values of hsCRP and 26% high values of pulse wave velocity.11.07% had ASCVD.Patients treated with nilotinib had a higher prevalence of dyslipidemia, smoking, peripheral arterial disease, and ASCVD.Conclusions: The prevalence of CVRF was higher than that described in the general Spanish population.Patients treated with nilotinib had a higher prevalence of uncontrolled hypertension, dyslipidemia, smoking, peripheral arterial disease, and established atherosclerotic cardiovascular disease than patients treated with imatinib and dasatinib.